Dr William Gray (Lankenau Heart Institute, Philadelphia, PA, US) discusses the DISRUPT PAD III randomised controlled trial (RCT), which provides the largest level one evidence for the treatment of heavily calcified femoropopliteal arteries. Results from the trial show that Shockwave’s intravascular lithotripsy (IVL) was superior to percutaneous transluminal angioplasty (PTA) in acute procedural success out to 30 days.

Questions:
1. What is the rationale of this study?
2. What were the study design, inclusion criteria and endpoints?
3. What were the key results?
4. What conclusions can be made?
5. What are the next steps?

Recorded remotely from Philadelphia, 2020.

Interviewer: Victoria Perroud
Recording editor: Natascha Wienand